Zhou L - Search Results

1

Population pharmacokinetic analysis of esomeprazole in Japanese subjects with various CYP2C19 phenotypes.

Nagase M, Shimada H, Nii M, Ueda S, Higashimori M, Ichikawa K, Zhang L, Zhou L, Chen Y, Zhou D, Dunyak J, Al-Huniti N. Nagase M, et al. Among authors: zhou d, zhou l. J Clin Pharm Ther. 2020 Oct;45(5):1030-1038. doi: 10.1111/jcpt.13129. Epub 2020 Mar 30. J Clin Pharm Ther. 2020. PMID: 32227647

2

Physiologically based pharmacokinetic modelling to predict exposure differences in healthy volunteers and subjects with renal impairment: Ceftazidime case study.

Zhou L, Tong X, Sharma P, Xu H, Al-Huniti N, Zhou D. Zhou L, et al. Among authors: zhou d. Basic Clin Pharmacol Toxicol. 2019 Aug;125(2):100-107. doi: 10.1111/bcpt.13209. Epub 2019 Mar 28. Basic Clin Pharmacol Toxicol. 2019. PMID: 30739396 Free article.

3

Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development Strategies.

Zhou L, Higashimori M, Shen K, Zhang Z, Sheng J, Xu H, Horiuchi M, Ichikawa K, Al-Huniti N, Zhou D. Zhou L, et al. Among authors: zhou d. Clin Pharmacol Ther. 2019 Jun;105(6):1303-1320. doi: 10.1002/cpt.1352. Epub 2019 Feb 25. Clin Pharmacol Ther. 2019. PMID: 30802932 Review. No abstract available.

4

Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based pharmacokinetic modelling.

Zhou L, Sharma P, Yeo KR, Higashimori M, Xu H, Al-Huniti N, Zhou D. Zhou L, et al. Among authors: zhou d. Eur J Pharm Sci. 2019 Nov 1;139:105061. doi: 10.1016/j.ejps.2019.105061. Epub 2019 Aug 31. Eur J Pharm Sci. 2019. PMID: 31479720

5

Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.

Schalkwijk S, Zhou L, Cohen-Rabbie S, Jain L, Freshwater T, So K, He Z, Gioni I, Tomkinson H, Vishwanathan K, Zhou D. Schalkwijk S, et al. Among authors: zhou d, zhou l. Cancer Chemother Pharmacol. 2021 Aug;88(2):189-202. doi: 10.1007/s00280-021-04274-6. Epub 2021 Apr 26. Cancer Chemother Pharmacol. 2021. PMID: 33903938

6

Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens.

Cohen-Rabbie S, Zhou L, Vishwanathan K, Wild M, Xu S, Freshwater T, Jain L, Schalkwijk S, Tomkinson H, Zhou D. Cohen-Rabbie S, et al. Among authors: zhou d, zhou l. J Clin Pharmacol. 2021 Nov;61(11):1493-1504. doi: 10.1002/jcph.1935. Epub 2021 Jul 22. J Clin Pharmacol. 2021. PMID: 34196005 Free PMC article.

7

Acalabrutinib CYP3A-mediated drug-drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy.

Chen B, Zhou D, Wei H, Yotvat M, Zhou L, Cheung J, Sarvaria N, Lai R, Sharma S, Vishwanathan K, Ware J. Chen B, et al. Among authors: zhou d, zhou l. Br J Clin Pharmacol. 2022 Aug;88(8):3716-3729. doi: 10.1111/bcp.15278. Epub 2022 Mar 28. Br J Clin Pharmacol. 2022. PMID: 35165925 Free article.

8

A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER⁺ HER2^- Primary Breast Cancer.

Robertson JFR, Evans A, Henschen S, Kirwan CC, Jahan A, Kenny LM, Dixon JM, Schmid P, Kothari A, Mohamed O, Fasching PA, Cheung KL, Wuerstlein R, Carroll D, Klinowska T, Lindemann JPO, MacDonald A, Mather R, Maudsley R, Moschetta M, Nikolaou M, Roudier MP, Sarvotham T, Schiavon G, Zhou D, Zhou L, Harbeck N. Robertson JFR, et al. Among authors: zhou d, zhou l. Clin Cancer Res. 2020 Aug 15;26(16):4242-4249. doi: 10.1158/1078-0432.CCR-19-3387. Epub 2020 Mar 31. Clin Cancer Res. 2020. PMID: 32234755 Clinical Trial.

9

Oncology Combination Dose-Finding Study Design for Targeted and Immuno-Oncology Therapies.

Zhou L, Reddy MB, Mittapalli RK, Yang J, Yin D. Zhou L, et al. Clin Pharmacol Ther. 2024 Jan;115(1):29-35. doi: 10.1002/cpt.3085. Epub 2023 Nov 20. Clin Pharmacol Ther. 2024. PMID: 37881828 Review.

10

Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study.

Meric-Bernstam F, Calvo E, Lee KS, Moreno V, Park YH, Rha SY, Chalasani P, Zhong W, Zhou L, Pirie-Shepherd S, Leung ACF, Curigliano G. Meric-Bernstam F, et al. Among authors: zhou l. Mol Cancer Ther. 2023 Oct 2;22(10):1191-1203. doi: 10.1158/1535-7163.MCT-23-0101. Mol Cancer Ther. 2023. PMID: 37420274 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

31,265 results

Search Page